You are here: Welcome to the MPKB » Welcome to the MPKB » Diseases » Hypertension (high blood pressure)
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Next revisionBoth sides next revision
home:diseases:hypertension [01.04.2019] – [Notes and comments] sallieqhome:diseases:hypertension [01.04.2019] – [Recent research] sallieq
Line 111: Line 111:
  
  
-{{tag>disease symptoms arrange}}+The administration of olmesartan improved blood pressure, insulin, HOMA, visfatin and lipid profile in hypertensive obese women. Irbesartan improved blood pressure and lipid levels. (({{pubmed>long:21061834}})) 
 + 
 + 
 +Olmesartan ameliorated arterial stiffness in patients with hypertension, which may be involved in the reduction of serum A-FABP.   (({{pubmed>long:21063874}})) 
 + 
 +Given the involvement of oxidative stress and its signaling in atherogenesis, and the available evidence of olmesartan's vasoprotective, anti-inflammatory and antiatherosclerotic effects derived from clinical trials in humans, the results of our study provide a mechanistic rationale for the omelsartan's antioxidant and anti-inflammatory potential translation, in the long term, toward the antiatherosclerotic and antiremodeling effects reported on the clinical ground.  (({{pubmed>long:21504378}})) 
 + 
 +{{tag>disease symptoms }}
  
 ===== References ===== ===== References =====
Line 169: Line 176:
 <blockquote>Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women. (({{pubmed>long:21061834}})) <blockquote>Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women. (({{pubmed>long:21061834}}))
  
-http://www.ncbi.nlm.nih.gov/pubmed/21061834+http://www.ncbi.nlm.nih.gov/pubmed/21061834 (USED on page --- //Sallie Q 01.04.2019// )
  
 CONCLUSION: The administration of olmesartan improved blood pressure, insulin, HOMA, visfatin and lipid profile in hypertensive obese women. Irbesartan improved blood pressure and lipid levels. CONCLUSION: The administration of olmesartan improved blood pressure, insulin, HOMA, visfatin and lipid profile in hypertensive obese women. Irbesartan improved blood pressure and lipid levels.
Line 182: Line 189:
  
 ~~~~ ~~~~
 +(part below ref. USED on page ---  --- //Sallie Q 01.04.2019// )
 Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. (({{pubmed>long:21063874}})) Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. (({{pubmed>long:21063874}}))
  
Line 233: Line 240:
  
 PMID: PMID:
-21504378</blockquote> +21504378 (part  USED on page --- //Sallie Q 01.04.2019//</blockquote> 
home/diseases/hypertension.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.